Summary

Dr. Zonder has a lead role in Multiple Myeloma research at Karmanos Cancer Institute (http://www.karmanos.org/) , one of only 39 NCI Comprehensive Cancer Centers in the country. Dr. Zonder has had a specific interest in amyloidosis, multiple myeloma and closely related diseases since he was in Medical School at Wayne State University. He is a member of several professional societies including ASH, ASCO, International Amyloidois society and SWOG. Dr. Zonder's primary research interest is investigating new drug applications for malignant plasma cell disorders.

In addition to his role as the PI for 13 active myeloma trials and co-investigator for other 16 leukemia and lymphoma studies at the Karmanos Cancer Institute, Dr. Zonder was also the National Study Coordinator (PI) for the SWOG study S0232 - Dexamethasone +/- Lenalidomide for patients with newly diagnosed Multiple Myeloma, the results of which were published on a manuscript in Blood September 27th, 2010 (First Edition online)

Dr. Zonder was the national PI for a study for primary systemic (AL)-Amyloidosis evaluating the combination of melphalan, dexamethasone, and bortezomib. This study was coordinated at Karmanos by a highly motivated team of professional researchers. The most completed results of this study were presented at the International Amyloidosis symposium in Rome (April 2010)

Upcoming Event: Karmanos Myeloma and Amyloidosis Patient Day - free to all patients and their families regardless of where they currently receive their cancer therapy, this program will offer patient-friendly informational seminars addressing a variety of topics, good food, free massage, and information from local and national vendors, foundations, and support groups. Date: October 16th, 2010. If interested, please register at: https://www.karmanos.org/myelomaregistration. This is the second patient day symposium that Karmanos is organizing at the Palace of Auburn Hills. The first time, this event attracted about 250 participants.